The company expects to enroll approximately 85 patients at five medical centers in Poland. The entire study is expected to be about 880 head and neck cancer patients in over 48 hospitals enroll in 9 countries on three continents. CEL – SCI’s partners Teva Pharmaceuticals and Orient Euro Pharma will consult parts of the Phase III study in Israel and Taiwan respectively.. Studyences Phase III trial in head and neck cancer in PolandCEL-SCI Corporation announced today that the company has its global Phase III clinical trial for Multikin the the company’s flagship immunotherapy, at the Centrum Onkologii – in Instytut. Marii Sklodowskiej-Curie, Warsaw, the first clinical site in Poland and the first center in the EU. Currently, the study is actively recruiting patients in the United States and India.
A detailed description of the study can be found here.. CEL-SCI’s Phase III clinical trial is an open-label, randomized, controlled, multicenter study to determine whether Multikine administered prior to current standard of care for the treatment naive patients with advanced primary squamous cell carcinoma of the oral cavity / soft palate will overall overall survival rate compared with subjects treated with standard of care only. It is also the first study to be tried in the immunotherapy before any other traditional means of care will be given.Researchers , led by Professor Susan M. Lea the Sir William Dunn School of Pathology at the University Oxford and Professor Christoph M. Tang carried of the Centre Molecular Microbiology and Infection Biology at Imperial College , determined the structure of man factor in B, appropriate factor in H binding protein the meningitis bacterium.